WallStSmart

American Shared Hospital Service (AMS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 218783% more annual revenue ($66.57B vs $30.41M). MRK leads profitability with a 4.8% profit margin vs -5.8%. MRK earns a higher WallStSmart Score of 36/100 (F).

AMS

Avoid

35

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 4.0
Piotroski: 4/9Altman Z: 0.99

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMSUndervalued (+41.6%)

Margin of Safety

+41.6%

Fair Value

$3.92

Current Price

$1.47

$2.45 discount

UndervaluedFair: $3.92Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMS2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
19.2%8/10

19.2% revenue growth

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

AMS4 concerns · Avg: 2.3/10
Market CapQuality
$9.81M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

Altman Z-ScoreHealth
0.992/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AMS

The strongest argument for AMS centers on Price/Book, Revenue Growth. Revenue growth of 19.2% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : AMS

The primary concerns for AMS are Market Cap, Return on Equity, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AMS profiles as a growth stock while MRK is a value play — different risk/reward profiles.

AMS carries more volatility with a beta of 0.30 — expect wider price swings.

AMS is growing revenue faster at 19.2% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 35/100). AMS offers better value entry with a 41.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Shared Hospital Service

HEALTHCARE · MEDICAL CARE FACILITIES · USA

American Shared Hospital Services rents radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?